Health Action International (HAI)'s European 2018 work plan builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy and regulation. HAI’s work plan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy.

HAI will keep on addressing those factors affecting access to medicines, including Intellectual Property rights while campaigning to broaden public and policy support to alternative models of biomedical innovation that contribute to medicines affordability and ensure public return on public investment. Advice and support will be provided to measures enhancing generic competition while bolstering governments position in procurement and medicines price negotiations.
As a member of the HTA Network Stakeholders Pool, HAI will contribute to the work of the network and issue recommendations to ensure that collaborative efforts strengthen the quality and robustness of HTA systems in Europe with the ultimate goal to enhance the sustainability of healthcare systems. Regarding the little (or non-existing) added therapeutic value of many new medicines, HAI will seek policy and regulatory support for more robust frameworks for medicines market approval; this will include initiatives for more proactive and robust pharmacovigilance systems to further protect patients’ safety. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring an independent consumers’ voice to EMA’s discussions and public consultations. We will closely follow developments in public access to clinical data in the EU and issue recommendations for enhanced transparency. In addition, we will implement initiatives to promote rational use of medicines by healthcare professionals.


Health Action International’s (HAI) 2019 European workplan builds on previous successes supported by CHAFEA. It provides a response to persistent shortcomings in European medicines policy and regulation. HAI’s workplan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy. In 2019, HAI will continue to address factors affecting access to medicines, including Intellectual Property Rights (IPR) while campaigning to broaden public and policy support in the European Union for alternative models of biomedical innovation that prioritise unmet medical needs, contribute to medicines affordability and ensure public return on public investment. Through the ‘Our Medicines, Our Right’ Campaign, we will seek to broaden policy support to medicines price transparency and R&D costs, as well as needs driven R&D modelling. We will roll-out campaign activities in Germany and thereby build bridges between policy discussions at the EU and Member State level. HAI will, furthermore, implement initiatives to promote responsible use of medicines, including antibiotics, by healthcare professionals. As a member of the Health Technology Assessment (HTA) Network Stakeholders Pool, HAI will contribute to the work programme of the network and advocate for strengthened EU collaboration on HTA. We will advocate specifically for joint HTA to be driven by high evaluation standards, transparency and independence from commercial interests. HAI will also seek policy and regulatory support for a more robust EU framework for medicines market authorization, in particular for cancer medicines. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring an independent consumers’ voice to EMA’s discussions and public consultations.


Oncology is undoubtedly currently the fastest developing area of healthcare. More or less every month new drugs come to the market; many of them are formulations for oral administration. This means that the complex treatment of often co-morbid oncology patients is moving from a supervised hospital setting to the patient’s home and dispensing of potent oral anticancer drugs to general community pharmacies. Pharmacists in such pharmacies are not specialized in care for oncology patients, since the curriculum of pharmacy studies includes few oncology-related topics.
Our purpose is to empower pharmacists to improve therapy-related outcomes and patient safety by lending support for the pharmaceutical counselling related to the dispensing of oral anticancer drugs. By doing so in selected member countries, we will create a best-practice model for the EU.
To this end, we will first survey the current situation and problems at dispensing of oral anticancer drugs in the EU. Based on the results we will design optimal post-graduate education for pharmacists about oncology topics and develop IT-tools that assist the pharmaceutical counselling process. This will allow the pharmacist quick access to essential information on oral oncology drugs including important advice for patients as well as useful service options like the preparation of treatment plans for the patient. By evaluating user satisfaction with the IT-tools and educational programme and subsequent implementation of improvements, we establish a ‘learning system’. This system will be put to effect in the participating partner countries and later made available for implementation in other EU-countries.
These measures will improve patients’ self-efficacy regarding his or her disease and therapy and, consequently, will enhance adherence.


Stichting (Foundation) Health Action International's European multi-annual programme 2018-2021 builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy. HAI’s work plan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy.

In particular, HAI will campaign to broaden public and policy support to alternative models of biomedical innovation that contribute to medicines affordability and ensure public return on public investment. We will also provide advice and support initiatives that enhance generic competition and empower governments in medicines price negotiations. As a member of the HTA Network Stakeholders Pool for the mandate 2016-2020, HAI will contribute to the work of Stakeholders Pool and issue recommendations to ensure that collaborative efforts strengthen the quality and robustness HTA systems in Europe with the ultimate goal to enhance the sustainability of healthcare systems and medical innovation. Following concerns about the little (or non-existing) added therapeutic value of many new medicines, HAI will seek policy and regulatory support for more robust frameworks for medicines. We will support initiatives for more proactive and robust pharmacovigilance systems to further protect patients’ safety. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring independent consumers’ voice to EMA’s policies and initiatives. We will follow closely developments on public access to clinical data in the EU and issue recommendations for enhanced transparency. In addition, we will implement initiatives for enhanced rational use of medicines for example by capacitating healthcare professionals to better assess information on medicines.
